<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111012</article-id><article-id pub-id-type="publisher-id">ACM-39724</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_91941413.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  前列腺癌放射性粒子植入后并发溃疡性结肠炎1例并文献复习
  Ulcerative Colitis after Implantation of Radioactive Seeds for Prostate Cancer: A Case Report
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>彬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韩</surname><given-names>雪阳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>诗璋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>良慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>侯</surname><given-names>四川</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属青岛市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>87</fpage><lpage>91</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    回顾分析我院1例前列腺癌(prostatic cancer, PC)放射性粒子(125I)植入后并发溃疡性结肠炎(ulcerative colitis, UC)患者的临床资料，加强对PC放射性粒子植入后便血的理解与认识。PC放射性粒子植入术后出现腹泻、便血时，我们应该意识到除了放射性结肠炎，还有UC的可能，应行结肠镜检查，早诊断，早治疗。
    The clinicopathological data of a patient with ulcerative colitis (UC) after implantation of prostatic cancer (PC) radioactive seeds (125I) in our hospital were retrospectively analyzed, to strengthen the understanding of blood in the stool after PC radioactive seeds implantation. When diarrhea and blood in the stool occur after PC radioactive seed implantation, we should be aware of the possibility of UC in addition to radiation colitis. Colonoscopy should be performed for early diagnosis and early treatment. 
  
 
</p></abstract><kwd-group><kwd>前列腺癌，近距离放射治疗，炎症性肠病，雄激素剥夺治疗, Prostate Cancer</kwd><kwd> Brachytherapy</kwd><kwd> Ulcerative Colitis</kwd><kwd> Androgen Deprivation Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>回顾分析我院1例前列腺癌(prostatic cancer, PC)放射性粒子(<sup>125</sup>I)植入后并发溃疡性结肠炎(ulcerative colitis, UC)患者的临床资料，加强对PC放射性粒子植入后便血的理解与认识。PC放射性粒子植入术后出现腹泻、便血时，我们应该意识到除了放射性结肠炎，还有UC的可能，应行结肠镜检查，早诊断，早治疗。</p></sec><sec id="s2"><title>关键词</title><p>前列腺癌，近距离放射治疗，炎症性肠病，雄激素剥夺治疗</p></sec><sec id="s3"><title>Ulcerative Colitis after Implantation of Radioactive Seeds for Prostate Cancer: A Case Report</title><p>Bin Li<sup>1</sup>, Xueyang Han<sup>2</sup>, Bo Jiang<sup>1</sup>, Shizhang Song<sup>1</sup>, Lianghui Jiang<sup>1</sup>, Sichuan Hou<sup>1</sup></p><p><sup>1</sup>Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/12-1571812x4_hanspub.png" /></p><p>Received: Dec. 11<sup>th</sup>, 2020; accepted: Dec. 26<sup>th</sup>, 2020; published: Jan. 12<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/12-1571812x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The clinicopathological data of a patient with ulcerative colitis (UC) after implantation of prostatic cancer (PC) radioactive seeds (<sup>125</sup>I) in our hospital were retrospectively analyzed, to strengthen the understanding of blood in the stool after PC radioactive seeds implantation. When diarrhea and blood in the stool occur after PC radioactive seed implantation, we should be aware of the possibility of UC in addition to radiation colitis. Colonoscopy should be performed for early diagnosis and early treatment.</p><p>Keywords:Prostate Cancer, Brachytherapy, Ulcerative Colitis, Androgen Deprivation Therapy</p><disp-formula id="hanspub.39724-formula5"><graphic xlink:href="//html.hanspub.org/file/12-1571812x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/12-1571812x7_hanspub.png" /> <img src="//html.hanspub.org/file/12-1571812x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>前列腺癌是常见的泌尿系统肿瘤，UC为慢性肠道炎症性疾病，常以腹泻、便血起病，病情反复，需终身治疗。有报道认为炎症性肠病(Inflammatory bowel disease, IBD)会增加前列腺癌的患病风险 [<xref ref-type="bibr" rid="hanspub.39724-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref2">2</xref>]。也有研究报道了前列腺癌放疗对UC的影响 [<xref ref-type="bibr" rid="hanspub.39724-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref4">4</xref>]，但这些研究都是先诊断为UC的PC患者，目前对于先诊断为PC然后发展成UC的报道较少。本文报道一个罕见病例，患者在前列腺癌<sup>125</sup>I植入术后并发溃疡性结肠炎。</p></sec><sec id="s6"><title>2. 临床资料</title><p>患者，男，73岁，因“查体发现前列腺特异性抗原(prostate-specific antigen, PSA)升高(164.6 ng/mL) 1月”入院，既往体健。专科查体：前列腺II增大，质硬，无触痛。睾酮：32.65 ng/dL，泌尿系超声检查：前列腺大小5.9 &#215; 4.6 &#215; 4.3 cm，实质回声不均匀；前列腺核磁：横断面前列腺边界欠清，前列腺增生，前列腺癌。于我院穿刺病理诊断为前列腺癌，Gleason分级4 + 4 = 8分。2019年8月患者开始口服比卡鲁胺(50 mg，每日一次)，3个月后患者PSA水平降低(0.588 ng/mL)，遂行放射性粒子植入术，共植入<sup>125</sup>I 89颗。术后联合内分泌治疗，术后1月复查PSA进一步降低(0.023 ng/mL)，睾酮：15.375 ng/dL，无其它并发症。术后5月患者开始出现腹泻、便血，约3次/日，伴里急后重感，门诊以放射性结肠炎治疗。之后患者上述状进行性加重，腹泻次数 &gt; 10次/天。入院体格检查：腹部平软，无压痛或肿胀。实验室检查：红细胞3.2 &#215; 10<sup>12</sup>/L (低) (4.3~5.8 &#215; 10<sup>12</sup>/L)，血红蛋白110 g/L (低) (130~175 g/L)，白细胞4.91 &#215; 10<sup>9</sup>/L (3.5~9.5 &#215; 10<sup>9</sup>/L)，血小板269 &#215; 10<sup>9</sup>/L (125~350 &#215; 10<sup>9</sup>/L)，总蛋白64.05 g/L (65~85 g/L)，白蛋白30.49 g/L (低) (40~55 g/L)，CRP 50.62 mg/L (高) (0~6 mg/L)，粪便常规隐血试验(+)，结肠镜显示脾曲结肠粘膜充血、水肿，弥漫性红斑及散在出血，多发糜烂及浅溃疡(如图1)。转入消化内科行美沙拉嗪抗炎，庆大霉素灌肠，匹维溴铵等治疗，目前无粘液脓血便，已排黄色成型软便，出院后仍需继续口服药物治疗。</p><p>图1. 患者部分肠镜所见</p></sec><sec id="s7"><title>3. 讨论</title><p>前列腺癌是常见的泌尿系统肿瘤，也是男性死于癌症的第三大原因 [<xref ref-type="bibr" rid="hanspub.39724-ref5">5</xref>]。目前，前列腺癌有几种成功的治疗方法，包括手术、放疗和积极监测。对于放射治疗，尤其是近距离放射治疗，由于具有疗效好、损伤小、并发症少的优点，放疗中常采用此方法。PC放射性粒子植入术后出现腹泻、便血，通常考虑为放射性结肠炎，极易忽视其它病变，而UC常表现为反复发作的腹泻、粘液脓血便及腹痛，需终生治疗，对患者的生理及心理产生巨大影响。目前PC患者<sup>125</sup>I植入术后并发UC的报道较少。</p><p>本例患者术后5月出现腹泻、便血，考虑为放射性结肠炎，但患者腹泻、便血症状进行性加重，结肠镜检查结果为UC。对于是辐射还是患者前列腺癌导致的溃疡性结肠炎，目前未发现相关报道。但既往有溃疡性结肠炎患者伴发前列腺癌后行放疗的研究，这些患者都是先诊断为UC后再确诊为PC的患者。研究认为：合并IBD和PC的患者，放疗不应成为禁忌，可以考虑行近距离放射治疗。短期内近距离放射治疗对IBD患者是安全且耐受性良好的，并不会加重IBD的症状。</p><p>我们推断放疗可能通过以下两种机制引起溃疡性结肠炎。一种是放疗引起肠道菌群的失调，引起肠道的炎症反应。既往实验已经证明肠道菌群与UC的发病密切相关 [<xref ref-type="bibr" rid="hanspub.39724-ref6">6</xref>]，正常情况下，肠道菌群可作为体内稳态器官，参与体内多种复杂的生理过程，维持肠黏膜的完整性以及病原微生物的清除 [<xref ref-type="bibr" rid="hanspub.39724-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref7">7</xref>]。正常的肠道微生物群可对抗肠道病原体在肠道的定植，益生菌则可以修复异常的黏膜屏障，维持肠道菌群的平衡，增强免疫力和肠道屏障功能。当有益菌明显缺乏或有害菌增加时，肠道正常保护功能降低，从而引起机体免疫力下降，当外部有害因素增加时，就会引起肠道黏膜浸润或加重肠炎反应 [<xref ref-type="bibr" rid="hanspub.39724-ref8">8</xref>]。同时肠道具有由双层的结肠黏液组成的物理屏障功能，保护机体抵抗肠道细菌。有研究报道，肠道微生物群可以影响结肠黏液层的性质，肠黏液层的破裂导致肠道细菌入侵，最终导致炎症和感染 [<xref ref-type="bibr" rid="hanspub.39724-ref9">9</xref>]。当黏液屏障被打破并且防御力减轻之后，炎症将会发生。</p><p>另一种是放疗将影响上皮间质转化(epithelial-mesenchymal transition, EMT)从而导致肠纤维化。EMT是指在某些因素下，上皮细胞丧失细胞连接与极性，且上皮细胞标志物逐渐消失而间质细胞标志物逐渐增多的过程。肠纤维化是IBD发展过程中不可避免的过程，其主要病理改变是以胶原为主的细胞外基质 (extracellular matrix, ECM)在肠组织的过度合成和异常沉积。Flier等 [<xref ref-type="bibr" rid="hanspub.39724-ref10">10</xref>] 将IBD患者术后肠组织标本冰冻切片行免疫荧光染色，可见上皮细胞标志物体E细胞钙黏蛋白(E-cadherin)及间质细胞标志物平滑肌激动蛋白(α-smooth muscle actin, α-SMA)，再次证实了EMT在IBD患者肠纤维化中发挥作用。</p><p>有研究报道了IBD和PC风险的相关性，患有IBD的男性PC发病率(10年时为4.4%)明显高于对照组(10年时为0.65%) [<xref ref-type="bibr" rid="hanspub.39724-ref11">11</xref>]。也有研究报道IBD患者患PC的风险显著增加(相对风险：1.70；标准化发病率：2.47) [<xref ref-type="bibr" rid="hanspub.39724-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref13">13</xref>]。IBD如何增加前列腺癌风险的潜在病理生理学有几种可能：一种可能性是与IBD相关的局部或全身炎症可能导致前列腺炎，使IBD患者易患前列腺癌 [<xref ref-type="bibr" rid="hanspub.39724-ref11">11</xref>]。另一种可能性是促炎细菌通过血流或尿路从胃肠道转移到前列腺，导致前列腺慢性炎症，进而增加患前列腺癌的风险 [<xref ref-type="bibr" rid="hanspub.39724-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref14">14</xref>]。前列腺癌和炎症性肠病的共同遗传易感性也被认为是一种可能的解释 [<xref ref-type="bibr" rid="hanspub.39724-ref11">11</xref>]。</p><p>对于放疗在IBD患者中的安全性已有相关研究 [<xref ref-type="bibr" rid="hanspub.39724-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref15">15</xref>]。对盆腔放疗与IBD患者相关性的研究表明，只有直肠部位的IBD或体重指数较低的患者在放疗后6个月内或之后IBD进一步加重 [<xref ref-type="bibr" rid="hanspub.39724-ref15">15</xref>]。一项研究评估了100名患有IBD的退伍军人的IBD特异性结局，结果显示，与IBD相关的住院率和与IBD相关的手术率与是否接受放疗并没有显著差异，放疗对远期预后并没有差异 [<xref ref-type="bibr" rid="hanspub.39724-ref3">3</xref>]。</p><p>然而，由于患者先进行了性激素剥夺治疗(androgen deprivation therapy, ADT)，我们也不能排除ADT导致UC的可能。ADT是晚期前列腺癌的主要治疗方法。通过降低雄激素水平，ADT可以抑制前列腺癌的进展。虽然雄激素在前列腺癌的发生中起着重要作用，但这些激素也可能调节人体免疫的某些方面 [<xref ref-type="bibr" rid="hanspub.39724-ref16">16</xref>]。但目前关于ADT引起的免疫效应研究仍然有限，性激素(如雄激素和雌激素)可能在自身免疫的发病机制中起作用的假设是基于几种自身免疫性疾病的性别差异，如系统性红斑狼疮、多发性硬化症和肾小球基底膜疾病 [<xref ref-type="bibr" rid="hanspub.39724-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.39724-ref19">19</xref>]。现在有研究表明，炎症性肠病在男女的发病率无明显差别，但可能受到外源性激素的使用的影响，如口服避孕药和激素替代疗法 [<xref ref-type="bibr" rid="hanspub.39724-ref20">20</xref>]。这可能表明性激素、免疫系统、粘膜屏障的变化以及促进肠道炎症的肠道微生物群之间存在复杂的相互作用。因此，ADT可能影响IBD的发病。</p><p>目前对患者在发展为PC后被诊断为UC及患者在放射性粒子植入术后发展为UC的报道较少，本例中患者的UC症状是在他的PC进行放射性粒子植入术后开始的。通过这个案例，我们可以推断以下三个假设：1) 放疗可能会引起结肠免疫反应，引发UC；2) 放疗不会引起UC，ADT会影响IBD的发病；3) 放疗和(或) ADT恰好与UC的发病时间一致，与UC的发病无关。</p><p>当PC患者在接受放射治疗或者行ADT治疗时出现腹泻、便血，除了放射性结肠炎外，我们还应意识到UC的可能性，并考虑结肠镜检查。</p></sec><sec id="s8"><title>同意书</title><p>该文章已获得患者本人的知情同意。</p></sec><sec id="s9"><title>文章引用</title><p>李 彬,韩雪阳,姜 波,宋诗璋,姜良慧,侯四川. 前列腺癌放射性粒子植入后并发溃疡性结肠炎1例并文献复习Ulcerative Colitis after Implantation of Radioactive Seeds for Prostate Cancer: A Case Report[J]. 临床医学进展, 2021, 11(01): 87-91. https://doi.org/10.12677/ACM.2021.111012</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39724-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J. and Feagins, L.A. (2020) Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer. Digestive Diseases and Sciences, 65, 22-30. &lt;br&gt;https://doi.org/10.1007/s10620-019-05934-7</mixed-citation></ref><ref id="hanspub.39724-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mohammed, W., Hoskin, P., Henry, A., Gomez-Iturriaga, A., Robinson, A. and Nikapota, A. (2018) Short-Term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Clinical Oncology, 30, 534-538. &lt;br&gt;https://doi.org/10.1016/j.clon.2018.06.007</mixed-citation></ref><ref id="hanspub.39724-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Feagins, L.A., Kim, J., Chandrakumaran, A., Gandle, C., Naik, K.H., Cipher, D.J., et al. (2020) Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated with Radiation Therapy. Inflammatory Bowel Diseases, 26, 728-733. &lt;br&gt;https://doi.org/10.1093/ibd/izz175</mixed-citation></ref><ref id="hanspub.39724-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Gestaut, M.M. and Swanson, G.P. (2017) Long Term Clinical Toxicity of Radiation Therapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Reports of Practical Oncology &amp; Radiotherapy, 22, 77-82.  
&lt;br&gt;https://doi.org/10.1016/j.rpor.2016.10.005</mixed-citation></ref><ref id="hanspub.39724-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Litwin, M.S. and Tan, H.J. (2017) The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA, 317, 2532-2542.</mixed-citation></ref><ref id="hanspub.39724-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yao, P., Cui, M., Wang, H., Gao, H., Wang, L., Yang, T., et al. (2016) Quantitative Analysis of Intestinal Flora of Uygur and Han Ethnic Chinese Patients with Ulcerative Colitis. Gastroenterology Research and Practice, 2016, Article ID: 9186232. &lt;br&gt;https://doi.org/10.1155/2016/9186232</mixed-citation></ref><ref id="hanspub.39724-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Khan, I., Ullah, N., Zha, L., Bai, Y.R., Khan, A., Zhao, T., et al. (2019) Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens, 8, 126. 
&lt;br&gt;https://doi.org/10.3390/pathogens8030126</mixed-citation></ref><ref id="hanspub.39724-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Z.H., Zhu, C.X., Quan, Y.S., Yang, Z.Y., Wu, S., Luo, W.W., et al. (2018) Relationship between Intestinal Microbiota and Ulcerative Colitis: Mechanisms and Clinical Application of Probiotics and Fecal Microbiota Transplantation. World Journal of Gastroenterology, 24, 5-14. http://dx.doi.org/10.3748/wjg.v24.i1.5</mixed-citation></ref><ref id="hanspub.39724-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Schroeder, B.O. (2019) Fight Them or Feed Them: How the Intestinal Mucus Layer Manages the Gut Microbiota. Gastroenterology Report, 7, 3-12. &lt;br&gt;https://doi.org/10.1093/gastro/goy052</mixed-citation></ref><ref id="hanspub.39724-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Flier, S.N., Tanjore, H., Kokkotou, E.G., Sugimoto, H., Zeisberg, M. and Kalluri, R. (2010) Identification of Epithelial to Mesenchymal Transition as a Novel Source of Fibroblasts in Intestinal Fibrosis. The Journal of Biological Chemistry, 285, 20202-20212. &lt;br&gt;https://doi.org/10.1074/jbc.M110.102012</mixed-citation></ref><ref id="hanspub.39724-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Burns, J.A., Weiner, A.B., Catalona, W.J., Li, E.V., Schaeffer, E.M., Hanauer, S.B., et al. (2019) Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 75, 846-852. &lt;br&gt;https://doi.org/10.1016/j.eururo.2018.11.039</mixed-citation></ref><ref id="hanspub.39724-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mosher, C.A., Brown, G.R., Weideman, R.A., Crook, T.W., Cipher, D.J., Spechler, S.J., et al. (2018) Incidence of Colorectal Cancer and Extracolonic Cancers in Veteran Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 24, 617-623. &lt;br&gt;https://doi.org/10.1093/ibd/izx046</mixed-citation></ref><ref id="hanspub.39724-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">So, J., Tang, W., Leung, W.K., Li, M., Lo, F.H., Wong, M.T.L., et al. (2017) Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study. Inflammatory Bowel Diseases, 23, 2061-2068. 
&lt;br&gt;https://doi.org/10.1097/MIB.0000000000001240</mixed-citation></ref><ref id="hanspub.39724-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sfanos, K.S., Yegnasubramanian, S., Nelson, W.G. and De Marzo, A.M. (2018) The Inflammatory Microenvironment and Microbiome in Prostate Cancer Development. Nature Reviews Urology, 15, 11-24.  
&lt;br&gt;https://doi.org/10.1038/nrurol.2017.167</mixed-citation></ref><ref id="hanspub.39724-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Annede, P., Seisen, T., Klotz, C., Mazeron, R., Maroun, P., Petit, C., et al. (2017) Inflammatory Bowel Diseases Activity in Patients Undergoing Pelvic Radiation Therapy. Journal of Gastrointestinal Oncology, 8, 173-179. 
&lt;br&gt;https://doi.org/10.21037/jgo.2017.01.13</mixed-citation></ref><ref id="hanspub.39724-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Fijak, M. and Meinhardt, A. (2006) The Testis in Immune Privilege. Immunological Reviews, 213, 66-81. 
&lt;br&gt;https://doi.org/10.1111/j.1600-065X.2006.00438.x</mixed-citation></ref><ref id="hanspub.39724-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hughes, G.C. and Choubey, D. (2014) Modulation of Autoimmune Rheumatic Diseases by Oestrogen and Progesterone. Nature Reviews Rheumatology, 10, 740-751. &lt;br&gt;https://doi.org/10.1038/nrrheum.2014.144</mixed-citation></ref><ref id="hanspub.39724-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Quintero, O.L., Amador-Patarroyo, M.J., Montoya-Ortiz, G., Rojas-Villarraga, A. and Anaya, J.-M. (2012) Autoimmune Disease and Gender: Plausible Mechanisms for the Female Predominance of Autoimmunity. Journal of Autoimmunity, 38, J109-J119. &lt;br&gt;https://doi.org/10.1016/j.jaut.2011.10.003</mixed-citation></ref><ref id="hanspub.39724-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Beeson, P.B. (1994) Age and Sex Associations of 40 Autoimmune Diseases. The American Journal of Medicine, 96, 457-462. &lt;br&gt;https://doi.org/10.1016/0002-9343(94)90173-2</mixed-citation></ref><ref id="hanspub.39724-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Khalili, H., Higuchi, L.M., Ananthakrishnan, A.N., Richter, J.M., Feskanich, D., Fuchs, C.S., et al. (2013) Oral Contraceptives, Reproductive Factors and Risk of Inflammatory Bowel Disease. Gut, 62, 1153-1159. 
http://dx.doi.org/10.1136/gutjnl-2012-302362</mixed-citation></ref></ref-list></back></article>